Floré Clinical (San Diego, CA) announced a new distribution agreement with Evexia Diagnostics (Washington, CT) to bring Floré’s personalized microbiome mapping technology, GI SereniT, to Evexia’s 20,000 clinical practitioners. Evexia Diagnostics is a cutting-edge platform that directly links clinicians with the testing, diagnostic panels and health information they need to help patients. Together, the two are expanding access to precision nutrition solutions and advancing the effort to make personalized microbiome testing part of the standard of care in clinical settings.
GI SereniT offers comprehensive stool analysis via Whole Genome Sequencing (WGS) of the gut microbiome. The at-home stool test provides patients with clinically relevant insight into gut dysbiosis, microbiome diversity, pathogenic bacteria, irritable bowel syndrome (IBS), irritable bowel disease (IBD) and more. It identifies more than 25,000 organism species while revealing information about gastrointestinal (GI) symptoms that many suffer from, such as gas, bloating and stomach pain, according to the company. After receiving the results, Floré creates a custom probiotic/prebiotic formula optimized for patients’ gut health.
“About 15 percent of the population suffers from unresolved gastrointestinal issues. Leveraging advanced microbiome mapping methods, personalized gut health testing technology like GI SereniT helps people get to the root cause of their health problems faster,” said Sunny Jain, founder and chief executive officer of Floré. “Enabled by Evexia’s vast network of clinicians and laboratory services, we’re proud to bring these offerings to more people than ever before, and create custom, meaningful solutions that provide lasting effects on patients’ health.”
Evexia Diagnostics stands out in the clinical laboratory services landscape, primarily catering to the functional and integrative medicine communities. Founded in 2007, Evexia has carved a niche by offering comprehensive, cutting-edge laboratory services at affordable prices. The organization’s proprietary infrastructure is tailored to meet the needs of both licensed and non-licensed clinicians, focusing on delivering fast and reliable solutions to enhance client efficiency and profitability.
“Floré Clinical is doing something special. They are delivering next-generation testing by equipping providers with interpretation as well as the solution,” said Ryan Obermeier, vice president and chief commercial officer of Evexia Diagnostics. “I believe as Floré Clinical continues to see success by offering unilateral solutions to healthcare practitioners, we will see a series of ‘Me Too’ companies following their footsteps in the trail they have blazed in the industry.”
For more information, visit www.evexiadiagnostics.com, www.floreclinical.com or www.flore.com.
